Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hormone Use
100%
Biomarker Profile
100%
Cardiovascular Biomarkers
100%
Trans Women
100%
Cisgender
100%
HIV Seropositive
100%
Hormonal Therapy
57%
Feminizing
57%
Cardiovascular Risk Factors
42%
People Living with HIV (PLHIV)
28%
HIV+
28%
Interleukin-8
28%
Plasminogen Activator inhibitor-1 (PAI-1)
28%
Receptor for Advanced Glycation End Products
28%
Endothelin 1 (ET-1)
28%
Oxidized Low-density Lipoprotein (ox-LDL)
28%
Non-Hispanic White
14%
Inflammation
14%
Cardiovascular Disease
14%
P-selectin
14%
Von Willebrand Factor
14%
Multiple Linear Regression
14%
Multivariable
14%
Fisher's Exact Test
14%
Wilcoxon Rank Sum Test
14%
Systemic Inflammation
14%
Interleukin-6
14%
Current Smokers
14%
Multicenter AIDS Cohort Study
14%
Black Hispanic
14%
Houston
14%
Soluble CD14 (sCD14)
14%
Texas
14%
Abacavir
14%
Biomarker Concentration
14%
Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
14%
Women with HIV
14%
Inflammation-related Diseases
14%
Tumor Necrosis Factor Receptor 1 (TNFR1)
14%
Low Von Willebrand Factor
14%
Medicine and Dentistry
Biological Marker
100%
Human Immunodeficiency Virus
100%
Cardiovascular System
100%
Transgender
90%
Cardiovascular Disease
36%
Hormone Therapy
36%
Endothelin 1
18%
Von Willebrand Factor
18%
Advanced Glycation End Product Receptor
18%
Oxidized Low Density Lipoprotein
18%
Interleukin 8
18%
Inflammation
18%
Plasminogen Activator Inhibitor-1
18%
Cohort Analysis
9%
Fisher Exact Test
9%
Acquired Immune Deficiency Syndrome
9%
Interleukin 6
9%
Linear Regression Analysis
9%
Fibrinogen
9%
Enzyme Linked Immunosorbent Assay
9%
PADGEM Protein
9%
Substance Use
9%
Tumor Necrosis Factor Receptor 1
9%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
9%
Abacavir
9%
Neuroscience
Human Immunodeficiency Virus
100%
Cardiovascular System
100%
Biological Marker
100%
Hormone Therapy
36%
Von Willebrand Factor
18%
Endothelin 1
18%
Oxidized Low Density Lipoprotein
18%
Advanced Glycation End Product Receptor
18%
Interleukin 8
18%
Plasminogen Activator Inhibitor-1
18%
Interleukin 6
9%
Substance Abuse
9%
CD14
9%
ELISA
9%
Fibrinogen
9%
P-Selectin
9%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
9%
Tumor Necrosis Factor Receptor 1
9%
Abacavir
9%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Biological Marker
100%
Hormone Cancer Therapy
36%
Cardiovascular Disease
36%
Inflammation
18%
Von Willebrand Factor
18%
Interleukin 8
18%
Plasminogen Activator Inhibitor 1
18%
Endothelin 1
18%
Advanced Glycation End Product Receptor
18%
Oxidized Low Density Lipoprotein
18%
Enzyme-Linked Immunosorbent Assay
9%
Acquired Immune Deficiency Syndrome
9%
Cohort Study
9%
P-Selectin
9%
Interleukin 6
9%
Fibrinogen
9%
Tumor Necrosis Factor Receptor 1
9%
1 Alkyl 2 Acetylglycerophosphocholine Esterase
9%
Abacavir
9%
Biochemistry, Genetics and Molecular Biology
Human Immunodeficiency Virus
100%
Endothelin 1
18%
Von Willebrand Factor
18%
Plasminogen Activator Inhibitor-1
18%
Interleukin 8
18%
Advanced Glycation End-Product
18%
Low-Density Lipoprotein
18%
Cohort Study
9%
Interleukin 6
9%
P-Selectin
9%
CD14
9%
Tumor Necrosis Factor Receptor
9%
Substance Use
9%
Lipoprotein-Associated Phospholipase A2
9%
Fibrinogen
9%
Abacavir
9%